Bioventus to sell $415M in senior notes

Bioventus intends to sell $415 million worth of senior notes in a private offering. 

Advertisement

The orthobiologics company  said in an April 26 news release it plans to put the profits from the sale toward its acquisition of medical device company CartiHeal. The proceeds will go toward repaying outstanding debts, covering costs associated with the sale and other corporate purposes.

The senior notes are not registered under the Securities Act of 1933, meaning they cannot be offered or sold in the U.S.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.